Literature DB >> 24472365

Remission of C3 glomerulopathy with rituximab as only immunosuppressive therapy.

Philippe Giaime, Laurent Daniel, Stéphane Burtey.   

Abstract

C3 glomerulopathy (C3GP) is a membranoproliferative glomerulonephritis without immunoglobulin deposits. Activation of the alternative pathway of the complement system is central in its pathogenesis. The presence of a C3 nephritic factor (C3Nef), or deficient factor H or I is associated with C3 GP. The treatment is not codified. Here we describe a case of a Caucasian male with a dense deposit disease (a form of C3GP) revealed by nephritic syndrome. C3Nef was present. We treated him with rituximab as the sole immunosuppressive regimen and obtained a complete remission on proteinuria. The effect was sustained at more than 2 years with only two courses of treatment and an excellent tolerance. Rituximab could be proposed as a treatment of C3GP associated with antibodies interfering with complement alternative pathway.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 24472365     DOI: 10.5414/CN107945

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  13 in total

Review 1.  [Membranoproliferative glomerulonephritis and C3 glomerulopathy].

Authors:  B Hohenstein; K Amann; J Menne
Journal:  Internist (Berl)       Date:  2019-05       Impact factor: 0.743

2.  Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy: A Case Series.

Authors:  Rupali S Avasare; Pietro A Canetta; Andrew S Bomback; Maddalena Marasa; Yasar Caliskan; Yasemin Ozluk; Yifu Li; Ali G Gharavi; Gerald B Appel
Journal:  Clin J Am Soc Nephrol       Date:  2018-01-11       Impact factor: 8.237

Review 3.  Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach.

Authors:  An S De Vriese; Sanjeev Sethi; Jens Van Praet; Karl A Nath; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2015-07-16       Impact factor: 10.121

4.  Use of Rituximab as an Off-Label Medication in Glomerular Diseases: Clinical Perspective.

Authors:  Ali AlSahow; Abdullah Al-Muhaiteeb; Hani Nawar; Bassam AlHelal; Anas AlYousef; Emad Abdallah; Ahmad AbuShall; Sameh Elmekawi; Basem Meshal; Ahmed AlQallaf; Heba AlRajab
Journal:  Med Princ Pract       Date:  2022-01-12       Impact factor: 2.132

5.  Effectiveness of mycophenolate mofetil in C3 glomerulonephritis.

Authors:  Cristina Rabasco; Teresa Cavero; Elena Román; Jorge Rojas-Rivera; Teresa Olea; Mario Espinosa; Virginia Cabello; Gema Fernández-Juarez; Fayna González; Ana Ávila; José María Baltar; Montserrat Díaz; Raquel Alegre; Sandra Elías; Monserrat Antón; Miguel Angel Frutos; Alfonso Pobes; Miguel Blasco; Francisco Martín; Carmen Bernis; Manuel Macías; Sergio Barroso; Alberto de Lorenzo; Gema Ariceta; Manuel López-Mendoza; Begoña Rivas; Katia López-Revuelta; José María Campistol; Santiago Mendizábal; Santiago Rodríguez de Córdoba; Manuel Praga
Journal:  Kidney Int       Date:  2015-07-29       Impact factor: 10.612

Review 6.  Update on C3 glomerulopathy.

Authors:  Thomas D Barbour; Marieta M Ruseva; Matthew C Pickering
Journal:  Nephrol Dial Transplant       Date:  2014-10-17       Impact factor: 5.992

7.  Treating C3 glomerulopathy with eculizumab.

Authors:  Thomas Welte; Frederic Arnold; Julia Kappes; Maximilian Seidl; Karsten Häffner; Carsten Bergmann; Gerd Walz; Elke Neumann-Haefelin
Journal:  BMC Nephrol       Date:  2018-01-12       Impact factor: 2.388

Review 8.  C3 glomerulopathy and current dilemmas.

Authors:  Naoko Ito; Ryuji Ohashi; Michio Nagata
Journal:  Clin Exp Nephrol       Date:  2016-11-23       Impact factor: 2.801

Review 9.  Diseases of complement dysregulation-an overview.

Authors:  Edwin K S Wong; David Kavanagh
Journal:  Semin Immunopathol       Date:  2018-01-11       Impact factor: 9.623

Review 10.  Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies.

Authors:  Michael Rudnicki
Journal:  Biomed Res Int       Date:  2017-05-09       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.